Celldex Therapeutics
CLDX
CLDX
160 hedge funds and large institutions have $1.78B invested in Celldex Therapeutics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 55 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
17% less capital invested
Capital invested by funds: $2.15B → $1.78B (-$367M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Holders
160
Holding in Top 10
3
Calls
$19.4M
Puts
$8.18M
Top Buyers
| 1 | +$28.1M | |
| 2 | +$25.8M | |
| 3 | +$20.7M | |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$15.1M |
| 5 |
Morgan Stanley
New York
|
+$10.4M |
Top Sellers
| 1 | -$16.8M | |
| 2 | -$12.2M | |
| 3 | -$12M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.94M |
| 5 |
SC
Sessa Capital
New York
|
-$9.45M |